JENA/Germany, 12.02.2018. Following on from its strong year-end results, Carl Zeiss Meditec AG continued its growth trend in the first quarter of 2017/18. Revenue increased by 5.3 percent (adjusted for currency effects: 9.5 percent), to €294.7m (prior year: €280.0m). Earnings before interest and taxes (EBIT) amounted to €38.9m; the adjusted EBIT margin was 13.5 percent (prior year: 13.4 percent).

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, had the following to say about results for the quarter: 'Our Company remains on course for growth, with encouraging contributions from both strategic business units and all regions. Targeted investments in refreshing our product portfolio in the areas of Ophthalmology and Microsurgery and in our global presence are therefore paying off for us.'

Highest Growth Rate In Microsurgery SBU


The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 4.2 percent in the first quarter of the current fiscal year (adjusted for currency effects: 8.2 percent), to €216.3m, compared with €207.6m in the same period of the prior year. This increase is attributable to all product areas - from ophthalmic diagnosis products through to lasers for refractive correction and intraocular lenses for cataract treatments, our business continued to grow.

Revenue in the Microsurgery SBU grew by 8.2 percent (adjusted for currency effects: 13.4 percent). Revenue from surgical microscopes and visualization solutions climbed to €78.4m, compared with €72.4m in the prior year.

Solid Growth In All Reporting Regions


Revenue in the EMEA region increased by 8.9 percent (adjusted for currency effects: 10.8 percent), resulting in total revenue of €91.2m (prior year: €83.7m). Business in the core markets of Germany and France developed well.

Revenue in the Americas region remained stable, increasing by 3.9 percent (adjusted for currency effects: 11.8 percent) to €94.1m (prior year: €90.5m).

Once again, there was a positive trend in the Asia/Pacific (APAC) region. At €109.5m, revenue was significantly higher than the prior-year figure of €105.8m - an increase of 3.5 percent (adjusted for currency effects: 6.6 percent). A large part of this growth is attributable to the Chinese market, as well as South Korea.

Earnings per share (EPS) amounted to €0.32, which was down slightly compared with the prior-year EPS of €0.38. This decrease is mainly due to the proceeds generated on the disposal of assets at the Ontario site, which were recognized in the first quarter of fiscal year 2016/17.

Carl Zeiss Meditec AG's objective for fiscal year 2017/18 continues to be to grow at at least the same rate as the underlying market. The EBIT margin is expected to be within the range also forecast for the medium term, of 14 to 16 percent on an adjusted basis.

Revenue By Strategic Business Unit



























Figures in €m
 3 Months
2017/18 		3 Months
2016/17 		Change from prior year Change from prior year*
Ophthalmic Devices 216.3 207.6 +4.2% +8.2%
Microsurgery 78.4 72.4 +8.2% +13.4%
Total 294.7 280.0 +5.3% +9.5%

* adjusted for currency effects

Revenue By Region
































Figures in €m
 3 Months
2017/18 		3 Months
2016/17 		Change from prior year Change from prior year*
EMEA 91.2 83.7 +8.9% +10.8%
Americas 94.1 90.5 +3.9% +11.8%
APAC 109.5 105.8 +3.5% +6.6%
Total 294.7 280.0 +5.3% +9.5%

* adjusted for currency effects

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Fax:
investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of €1,189.9m in fiscal year 2016/17 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at:
www.zeiss.com/med

Number: 0015-2018-ENG OP

Number of Words: 780
Number of Characters: 6188

Carl Zeiss Meditec AG published this content on 12 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 February 2018 09:25:04 UTC.

Original documenthttp://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/1383C09D49AD04E9C1258232001C94F1?OpenDocument

Public permalinkhttp://www.publicnow.com/view/479D3979335871FDEA843F1B143E584067658C28